RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Filing@palinc2000 You've been out front advocating for the ability and need for THTX to build their existing commercial portfolio. They seem to have a multi-pronged approach to scaling their business, and this is certainly one of the strategic initiatives. I'm hopeful they can continue to grow revenue from existing commercialized products through more education and direct relationships with doctor groups now that their sales team is in-house. It still seems reasonable that EGRIFTA would be more attractive due to the potential for multiple additional non-labeled benefits, which could drive sales higher. I know many on this board do not believe there's much additional life to the existing portfolio, but it's been encouraging to see some growth. I thought it was important that Paul pointed out the shorter lookback and sales growth compared to the year ago comparison. He clearly believes they are building momentum.